Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Dow
Fuji
QuintilesIMS
Accenture
US Army
Mallinckrodt
UBS
Medtronic
Deloitte

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,272,137

« Back to Dashboard

Which drugs does patent 9,272,137 protect, and when does it expire?


Patent 9,272,137 protects ZECUITY and is included in one NDA.

This patent has twenty patent family members in twelve countries.

Summary for Patent: 9,272,137

Title:Transdermal methods and systems for the delivery of anti-migraine compounds
Abstract: Iontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described.
Inventor(s): Anderson; Carter R. (Inver Grove Heights, MN), Morris; Russell L. (Lindstrom, MN), Sebree; Terri B. (Gladwyne, PA)
Assignee: Teva Pharmaceuticals International GmbH (Rapperswil-Jona, CH)
Application Number:13/105,562
Patent Claim Types:
see list of patent claims
Compound; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Teva Branded PharmZECUITYsumatriptan succinateSYSTEM;IONTOPHORESIS202278-001Jan 17, 2013DISCNYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,272,137

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,973,058Transdermal methods and systems for the delivery of anti-migraine compounds► Subscribe
8,470,853Transdermal methods and systems for the delivery of anti-migraine compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,272,137

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2650412► Subscribe
Canada2935569► Subscribe
China101472644► Subscribe
European Patent Office2012871► Subscribe
China104138634► Subscribe
Eurasian Patent Organization200802146► Subscribe
Eurasian Patent Organization023147► Subscribe
Hong Kong1203867► Subscribe
Israel194553► Subscribe
Japan2009533451► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Argus Health
US Army
Daiichi Sankyo
Queensland Health
Citi
McKinsey
Cantor Fitzgerald
Accenture
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot